Scemblix 40 mg film-coated tablets
CABL001AFR05
Phase 2 small_molecule active
Quick answer
Scemblix 40 mg film-coated tablets for CML-CP or CML-AP patients with T315I mutation is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- CML-CP or CML-AP patients with T315I mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active